Efficacy assessment
death, Tumor
DISEASE PROGRESSION, TUMOR
Tumor responses were evaluated based on RECIST 1.1 at screening and every two cycles until disease progression or the start of new antitumor treatment. The complete and partial response would be confirmed after 4 weeks. All the progression‐free survival (PFS) was defined as the time from the start of the first dose to disease progression or death of any cause. The overall survival was defined as the time from the start of the first dose to death. Survival status was obtained from medical records and followed up by telephone.